Acquisition Announced
BioMarin Pharmaceutical acquisition of Alesta Therapeutics
US$275m consideration
Announced 18 Aug 2026
Advisers
- Target
- Alesta Therapeutics
- Acquirer
- BioMarin Pharmaceutical
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Rare Disease, Drug Development
In the league tables
Similar deals
- Werewolf Therapeutics and Ambros Therapeutics merger Aug 2026 · US$500m · Biotech
- BioCryst Pharmaceuticals acquisition of Astria Therapeutics Oct 2025 · US$700m · Biotech
- Jazz Pharmaceuticals acquisition of Actio Biosciences Aug 2026 · US$820m · Biotech
- Incyte acquisition of Vega Therapeutics Jun 2026 · US$1.3bn · Biotech
- Servier acquisition of Sevasemten and Edgewise muscular dystrophy business Jun 2026 · US$1.6bn · Biotech
Sources
- 18 Aug 2026 Press release (EX-99.1, exhibit), BioMarin Pharmaceutical Inc. sec.gov
- 18 Aug 2026 Goodwin Advises Alesta Therapeutics in Acquisition by BioMarin for up to $490 Million goodwinlaw.com
- 18 Aug 2026 Press release (PR Newswire), BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline prnewswire.com



